カテゴリー： Market Monitor Global, 世界, 医療/バイオ

非メラノーマ皮膚がん治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Non-melanoma Skin Cancer Drugs Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU5811）

◆商品コード：MMG23JU5811
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月（※2025年版があります。お問い合わせください。）
◆ページ数：110
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品＆医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Non-melanoma Skin Cancer Drugs Market 調査レポートは次の情報を含め、グローバルにおけるの非メラノーマ皮膚がん治療薬市場規模と予測を収録しています。・世界の非メラノーマ皮膚がん治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の非メラノーマ皮膚がん治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の非メラノーマ皮膚がん治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「イミキモドクリーム」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

非メラノーマ皮膚がん治療薬のグローバル主要企業は、Pfizer、 Bausch Health、 Mayne Pharma、 Roche、 United Laboratories、 3M、 Perrigo、 Biological E.、 Glenmark Pharmaceuticals、 Sichuan Med-shine Pharmaceutical、 Henan Topfond Pharmaceutical、 Regeneron (Sanofi)、 Bristol-Myers Squibb、 Sun Pharma、 Qilu Pharmaceutical、 Hansoh Pharma、 Celgene Corporation、 Taj Accura、 Khandelwal Laboratories Pvt Ltd.、 Luye Pharma、 Beijing Youcare、 Beijing Union Pharmaceutical Factory、 Hainan Haiyao、 Chuntchなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、非メラノーマ皮膚がん治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の非メラノーマ皮膚がん治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の非メラノーマ皮膚がん治療薬市場：タイプ別市場シェア、2022年
・イミキモドクリーム、5-フルオロウラシルクリーム、ビスモデギブ、セミプリマブ、シスプラチン、パクリタキセル

世界の非メラノーマ皮膚がん治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の非メラノーマ皮膚がん治療薬市場：用途別市場シェア、2022年
・基底細胞癌（BCC）、扁平上皮癌（SCC）

世界の非メラノーマ皮膚がん治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の非メラノーマ皮膚がん治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における非メラノーマ皮膚がん治療薬のグローバル売上、2018年-2023年
・主要企業における非メラノーマ皮膚がん治療薬のグローバル売上シェア、2022年
・主要企業における非メラノーマ皮膚がん治療薬のグローバル販売量、2018年-2023年
・主要企業における非メラノーマ皮膚がん治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Pfizer、 Bausch Health、 Mayne Pharma、 Roche、 United Laboratories、 3M、 Perrigo、 Biological E.、 Glenmark Pharmaceuticals、 Sichuan Med-shine Pharmaceutical、 Henan Topfond Pharmaceutical、 Regeneron (Sanofi)、 Bristol-Myers Squibb、 Sun Pharma、 Qilu Pharmaceutical、 Hansoh Pharma、 Celgene Corporation、 Taj Accura、 Khandelwal Laboratories Pvt Ltd.、 Luye Pharma、 Beijing Youcare、 Beijing Union Pharmaceutical Factory、 Hainan Haiyao、 Chuntch

*************************************************************

・調査・分析レポートの概要
非メラノーマ皮膚がん治療薬市場の定義
市場セグメント
世界の非メラノーマ皮膚がん治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の非メラノーマ皮膚がん治療薬市場規模
世界の非メラノーマ皮膚がん治療薬市場規模：2022年 VS 2029年
世界の非メラノーマ皮膚がん治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの非メラノーマ皮膚がん治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の非メラノーマ皮膚がん治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：イミキモドクリーム、5-フルオロウラシルクリーム、ビスモデギブ、セミプリマブ、シスプラチン、パクリタキセル
非メラノーマ皮膚がん治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：基底細胞癌（BCC）、扁平上皮癌（SCC）
非メラノーマ皮膚がん治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別非メラノーマ皮膚がん治療薬市場規模 2022年と2029年
地域別非メラノーマ皮膚がん治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Pfizer、 Bausch Health、 Mayne Pharma、 Roche、 United Laboratories、 3M、 Perrigo、 Biological E.、 Glenmark Pharmaceuticals、 Sichuan Med-shine Pharmaceutical、 Henan Topfond Pharmaceutical、 Regeneron (Sanofi)、 Bristol-Myers Squibb、 Sun Pharma、 Qilu Pharmaceutical、 Hansoh Pharma、 Celgene Corporation、 Taj Accura、 Khandelwal Laboratories Pvt Ltd.、 Luye Pharma、 Beijing Youcare、 Beijing Union Pharmaceutical Factory、 Hainan Haiyao、 Chuntch
...

This report aims to provide a comprehensive presentation of the global market for Non-melanoma Skin Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-melanoma Skin Cancer Drugs. This report contains market size and forecasts of Non-melanoma Skin Cancer Drugs in global, including the following market information:
Global Non-melanoma Skin Cancer Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Non-melanoma Skin Cancer Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Imiquimod Cream Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Non-melanoma Skin Cancer Drugs include Pfizer, Bausch Health, Mayne Pharma, Roche, United Laboratories, 3M, Perrigo, Biological E. and Glenmark Pharmaceuticals, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-melanoma Skin Cancer Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-melanoma Skin Cancer Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Non-melanoma Skin Cancer Drugs Market Segment Percentages, by Type, 2022 (%)
Imiquimod Cream
5-fluorouracil Cream
Vismodegib
Cemiplimab
Cisplatin
Paclitaxel
Global Non-melanoma Skin Cancer Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Non-melanoma Skin Cancer Drugs Market Segment Percentages, by Application, 2022 (%)
Basal Cell Carcinoma (BCC)
Squamous Cell Carcinoma (SCC)
Global Non-melanoma Skin Cancer Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Non-melanoma Skin Cancer Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-melanoma Skin Cancer Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-melanoma Skin Cancer Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Bausch Health
Mayne Pharma
Roche
United Laboratories
3M
Perrigo
Biological E.
Glenmark Pharmaceuticals
Sichuan Med-shine Pharmaceutical
Henan Topfond Pharmaceutical
Regeneron (Sanofi)
Bristol-Myers Squibb
Sun Pharma
Qilu Pharmaceutical
Hansoh Pharma
Celgene Corporation
Taj Accura
Khandelwal Laboratories Pvt Ltd.
Luye Pharma
Beijing Youcare
Beijing Union Pharmaceutical Factory
Hainan Haiyao
Chuntch
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-melanoma Skin Cancer Drugs, market overview.
Chapter 2: Global Non-melanoma Skin Cancer Drugs market size in revenue.
Chapter 3: Detailed analysis of Non-melanoma Skin Cancer Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-melanoma Skin Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Non-melanoma Skin Cancer Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-melanoma Skin Cancer Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-melanoma Skin Cancer Drugs Overall Market Size
2.1 Global Non-melanoma Skin Cancer Drugs Market Size: 2022 VS 2029
2.2 Global Non-melanoma Skin Cancer Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-melanoma Skin Cancer Drugs Players in Global Market
3.2 Top Global Non-melanoma Skin Cancer Drugs Companies Ranked by Revenue
3.3 Global Non-melanoma Skin Cancer Drugs Revenue by Companies
3.4 Top 3 and Top 5 Non-melanoma Skin Cancer Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Non-melanoma Skin Cancer Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-melanoma Skin Cancer Drugs Players in Global Market
3.6.1 List of Global Tier 1 Non-melanoma Skin Cancer Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-melanoma Skin Cancer Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Non-melanoma Skin Cancer Drugs Market Size Markets, 2022 & 2029
4.1.2 Imiquimod Cream
4.1.3 5-fluorouracil Cream
4.1.4 Vismodegib
4.1.5 Cemiplimab
4.1.6 Cisplatin
4.1.7 Paclitaxel
4.2 By Type – Global Non-melanoma Skin Cancer Drugs Revenue & Forecasts
4.2.1 By Type – Global Non-melanoma Skin Cancer Drugs Revenue, 2018-2023
4.2.2 By Type – Global Non-melanoma Skin Cancer Drugs Revenue, 2024-2029
4.2.3 By Type – Global Non-melanoma Skin Cancer Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Non-melanoma Skin Cancer Drugs Market Size, 2022 & 2029
5.1.2 Basal Cell Carcinoma (BCC)
5.1.3 Squamous Cell Carcinoma (SCC)
5.2 By Application – Global Non-melanoma Skin Cancer Drugs Revenue & Forecasts
5.2.1 By Application – Global Non-melanoma Skin Cancer Drugs Revenue, 2018-2023
5.2.2 By Application – Global Non-melanoma Skin Cancer Drugs Revenue, 2024-2029
5.2.3 By Application – Global Non-melanoma Skin Cancer Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Non-melanoma Skin Cancer Drugs Market Size, 2022 & 2029
6.2 By Region – Global Non-melanoma Skin Cancer Drugs Revenue & Forecasts
6.2.1 By Region – Global Non-melanoma Skin Cancer Drugs Revenue, 2018-2023
6.2.2 By Region – Global Non-melanoma Skin Cancer Drugs Revenue, 2024-2029
6.2.3 By Region – Global Non-melanoma Skin Cancer Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Non-melanoma Skin Cancer Drugs Revenue, 2018-2029
6.3.2 US Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.3.3 Canada Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.3.4 Mexico Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Non-melanoma Skin Cancer Drugs Revenue, 2018-2029
6.4.2 Germany Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.4.3 France Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.4.4 U.K. Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.4.5 Italy Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.4.6 Russia Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.4.7 Nordic Countries Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.4.8 Benelux Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Non-melanoma Skin Cancer Drugs Revenue, 2018-2029
6.5.2 China Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.5.3 Japan Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.5.4 South Korea Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.5.5 Southeast Asia Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.5.6 India Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Non-melanoma Skin Cancer Drugs Revenue, 2018-2029
6.6.2 Brazil Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.6.3 Argentina Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Non-melanoma Skin Cancer Drugs Revenue, 2018-2029
6.7.2 Turkey Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.7.3 Israel Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.7.5 UAE Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
7 Non-melanoma Skin Cancer Drugs Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Non-melanoma Skin Cancer Drugs Major Product Offerings
7.1.4 Pfizer Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Bausch Health
7.2.1 Bausch Health Company Summary
7.2.2 Bausch Health Business Overview
7.2.3 Bausch Health Non-melanoma Skin Cancer Drugs Major Product Offerings
7.2.4 Bausch Health Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.2.5 Bausch Health Key News & Latest Developments
7.3 Mayne Pharma
7.3.1 Mayne Pharma Company Summary
7.3.2 Mayne Pharma Business Overview
7.3.3 Mayne Pharma Non-melanoma Skin Cancer Drugs Major Product Offerings
7.3.4 Mayne Pharma Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.3.5 Mayne Pharma Key News & Latest Developments
7.4 Roche
7.4.1 Roche Company Summary
7.4.2 Roche Business Overview
7.4.3 Roche Non-melanoma Skin Cancer Drugs Major Product Offerings
7.4.4 Roche Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.4.5 Roche Key News & Latest Developments
7.5 United Laboratories
7.5.1 United Laboratories Company Summary
7.5.2 United Laboratories Business Overview
7.5.3 United Laboratories Non-melanoma Skin Cancer Drugs Major Product Offerings
7.5.4 United Laboratories Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.5.5 United Laboratories Key News & Latest Developments
7.6 3M
7.6.1 3M Company Summary
7.6.2 3M Business Overview
7.6.3 3M Non-melanoma Skin Cancer Drugs Major Product Offerings
7.6.4 3M Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.6.5 3M Key News & Latest Developments
7.7 Perrigo
7.7.1 Perrigo Company Summary
7.7.2 Perrigo Business Overview
7.7.3 Perrigo Non-melanoma Skin Cancer Drugs Major Product Offerings
7.7.4 Perrigo Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.7.5 Perrigo Key News & Latest Developments
7.8 Biological E.
7.8.1 Biological E. Company Summary
7.8.2 Biological E. Business Overview
7.8.3 Biological E. Non-melanoma Skin Cancer Drugs Major Product Offerings
7.8.4 Biological E. Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.8.5 Biological E. Key News & Latest Developments
7.9 Glenmark Pharmaceuticals
7.9.1 Glenmark Pharmaceuticals Company Summary
7.9.2 Glenmark Pharmaceuticals Business Overview
7.9.3 Glenmark Pharmaceuticals Non-melanoma Skin Cancer Drugs Major Product Offerings
7.9.4 Glenmark Pharmaceuticals Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.9.5 Glenmark Pharmaceuticals Key News & Latest Developments
7.10 Sichuan Med-shine Pharmaceutical
7.10.1 Sichuan Med-shine Pharmaceutical Company Summary
7.10.2 Sichuan Med-shine Pharmaceutical Business Overview
7.10.3 Sichuan Med-shine Pharmaceutical Non-melanoma Skin Cancer Drugs Major Product Offerings
7.10.4 Sichuan Med-shine Pharmaceutical Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.10.5 Sichuan Med-shine Pharmaceutical Key News & Latest Developments
7.11 Henan Topfond Pharmaceutical
7.11.1 Henan Topfond Pharmaceutical Company Summary
7.11.2 Henan Topfond Pharmaceutical Business Overview
7.11.3 Henan Topfond Pharmaceutical Non-melanoma Skin Cancer Drugs Major Product Offerings
7.11.4 Henan Topfond Pharmaceutical Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.11.5 Henan Topfond Pharmaceutical Key News & Latest Developments
7.12 Regeneron (Sanofi)
7.12.1 Regeneron (Sanofi) Company Summary
7.12.2 Regeneron (Sanofi) Business Overview
7.12.3 Regeneron (Sanofi) Non-melanoma Skin Cancer Drugs Major Product Offerings
7.12.4 Regeneron (Sanofi) Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.12.5 Regeneron (Sanofi) Key News & Latest Developments
7.13 Bristol-Myers Squibb
7.13.1 Bristol-Myers Squibb Company Summary
7.13.2 Bristol-Myers Squibb Business Overview
7.13.3 Bristol-Myers Squibb Non-melanoma Skin Cancer Drugs Major Product Offerings
7.13.4 Bristol-Myers Squibb Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.13.5 Bristol-Myers Squibb Key News & Latest Developments
7.14 Sun Pharma
7.14.1 Sun Pharma Company Summary
7.14.2 Sun Pharma Business Overview
7.14.3 Sun Pharma Non-melanoma Skin Cancer Drugs Major Product Offerings
7.14.4 Sun Pharma Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.14.5 Sun Pharma Key News & Latest Developments
7.15 Qilu Pharmaceutical
7.15.1 Qilu Pharmaceutical Company Summary
7.15.2 Qilu Pharmaceutical Business Overview
7.15.3 Qilu Pharmaceutical Non-melanoma Skin Cancer Drugs Major Product Offerings
7.15.4 Qilu Pharmaceutical Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.15.5 Qilu Pharmaceutical Key News & Latest Developments
7.16 Hansoh Pharma
7.16.1 Hansoh Pharma Company Summary
7.16.2 Hansoh Pharma Business Overview
7.16.3 Hansoh Pharma Non-melanoma Skin Cancer Drugs Major Product Offerings
7.16.4 Hansoh Pharma Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.16.5 Hansoh Pharma Key News & Latest Developments
7.17 Celgene Corporation
7.17.1 Celgene Corporation Company Summary
7.17.2 Celgene Corporation Business Overview
7.17.3 Celgene Corporation Non-melanoma Skin Cancer Drugs Major Product Offerings
7.17.4 Celgene Corporation Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.17.5 Celgene Corporation Key News & Latest Developments
7.18 Taj Accura
7.18.1 Taj Accura Company Summary
7.18.2 Taj Accura Business Overview
7.18.3 Taj Accura Non-melanoma Skin Cancer Drugs Major Product Offerings
7.18.4 Taj Accura Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.18.5 Taj Accura Key News & Latest Developments
7.19 Khandelwal Laboratories Pvt Ltd.
7.19.1 Khandelwal Laboratories Pvt Ltd. Company Summary
7.19.2 Khandelwal Laboratories Pvt Ltd. Business Overview
7.19.3 Khandelwal Laboratories Pvt Ltd. Non-melanoma Skin Cancer Drugs Major Product Offerings
7.19.4 Khandelwal Laboratories Pvt Ltd. Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.19.5 Khandelwal Laboratories Pvt Ltd. Key News & Latest Developments
7.20 Luye Pharma
7.20.1 Luye Pharma Company Summary
7.20.2 Luye Pharma Business Overview
7.20.3 Luye Pharma Non-melanoma Skin Cancer Drugs Major Product Offerings
7.20.4 Luye Pharma Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.20.5 Luye Pharma Key News & Latest Developments
7.21 Beijing Youcare
7.21.1 Beijing Youcare Company Summary
7.21.2 Beijing Youcare Business Overview
7.21.3 Beijing Youcare Non-melanoma Skin Cancer Drugs Major Product Offerings
7.21.4 Beijing Youcare Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.21.5 Beijing Youcare Key News & Latest Developments
7.22 Beijing Union Pharmaceutical Factory
7.22.1 Beijing Union Pharmaceutical Factory Company Summary
7.22.2 Beijing Union Pharmaceutical Factory Business Overview
7.22.3 Beijing Union Pharmaceutical Factory Non-melanoma Skin Cancer Drugs Major Product Offerings
7.22.4 Beijing Union Pharmaceutical Factory Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.22.5 Beijing Union Pharmaceutical Factory Key News & Latest Developments
7.23 Hainan Haiyao
7.23.1 Hainan Haiyao Company Summary
7.23.2 Hainan Haiyao Business Overview
7.23.3 Hainan Haiyao Non-melanoma Skin Cancer Drugs Major Product Offerings
7.23.4 Hainan Haiyao Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.23.5 Hainan Haiyao Key News & Latest Developments
7.24 Chuntch
7.24.1 Chuntch Company Summary
7.24.2 Chuntch Business Overview
7.24.3 Chuntch Non-melanoma Skin Cancer Drugs Major Product Offerings
7.24.4 Chuntch Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.24.5 Chuntch Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Non-melanoma Skin Cancer Drugs Market Opportunities & Trends in Global Market
Table 2. Non-melanoma Skin Cancer Drugs Market Drivers in Global Market
Table 3. Non-melanoma Skin Cancer Drugs Market Restraints in Global Market
Table 4. Key Players of Non-melanoma Skin Cancer Drugs in Global Market
Table 5. Top Non-melanoma Skin Cancer Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Non-melanoma Skin Cancer Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Non-melanoma Skin Cancer Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Non-melanoma Skin Cancer Drugs Product Type
Table 9. List of Global Tier 1 Non-melanoma Skin Cancer Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-melanoma Skin Cancer Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Non-melanoma Skin Cancer Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Non-melanoma Skin Cancer Drugs Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Non-melanoma Skin Cancer Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Non-melanoma Skin Cancer Drugs Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Non-melanoma Skin Cancer Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Non-melanoma Skin Cancer Drugs Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 30. Pfizer Company Summary
Table 31. Pfizer Non-melanoma Skin Cancer Drugs Product Offerings
Table 32. Pfizer Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. Pfizer Key News & Latest Developments
Table 34. Bausch Health Company Summary
Table 35. Bausch Health Non-melanoma Skin Cancer Drugs Product Offerings
Table 36. Bausch Health Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Bausch Health Key News & Latest Developments
Table 38. Mayne Pharma Company Summary
Table 39. Mayne Pharma Non-melanoma Skin Cancer Drugs Product Offerings
Table 40. Mayne Pharma Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Mayne Pharma Key News & Latest Developments
Table 42. Roche Company Summary
Table 43. Roche Non-melanoma Skin Cancer Drugs Product Offerings
Table 44. Roche Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. Roche Key News & Latest Developments
Table 46. United Laboratories Company Summary
Table 47. United Laboratories Non-melanoma Skin Cancer Drugs Product Offerings
Table 48. United Laboratories Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. United Laboratories Key News & Latest Developments
Table 50. 3M Company Summary
Table 51. 3M Non-melanoma Skin Cancer Drugs Product Offerings
Table 52. 3M Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. 3M Key News & Latest Developments
Table 54. Perrigo Company Summary
Table 55. Perrigo Non-melanoma Skin Cancer Drugs Product Offerings
Table 56. Perrigo Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. Perrigo Key News & Latest Developments
Table 58. Biological E. Company Summary
Table 59. Biological E. Non-melanoma Skin Cancer Drugs Product Offerings
Table 60. Biological E. Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. Biological E. Key News & Latest Developments
Table 62. Glenmark Pharmaceuticals Company Summary
Table 63. Glenmark Pharmaceuticals Non-melanoma Skin Cancer Drugs Product Offerings
Table 64. Glenmark Pharmaceuticals Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 65. Glenmark Pharmaceuticals Key News & Latest Developments
Table 66. Sichuan Med-shine Pharmaceutical Company Summary
Table 67. Sichuan Med-shine Pharmaceutical Non-melanoma Skin Cancer Drugs Product Offerings
Table 68. Sichuan Med-shine Pharmaceutical Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 69. Sichuan Med-shine Pharmaceutical Key News & Latest Developments
Table 70. Henan Topfond Pharmaceutical Company Summary
Table 71. Henan Topfond Pharmaceutical Non-melanoma Skin Cancer Drugs Product Offerings
Table 72. Henan Topfond Pharmaceutical Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 73. Henan Topfond Pharmaceutical Key News & Latest Developments
Table 74. Regeneron (Sanofi) Company Summary
Table 75. Regeneron (Sanofi) Non-melanoma Skin Cancer Drugs Product Offerings
Table 76. Regeneron (Sanofi) Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 77. Regeneron (Sanofi) Key News & Latest Developments
Table 78. Bristol-Myers Squibb Company Summary
Table 79. Bristol-Myers Squibb Non-melanoma Skin Cancer Drugs Product Offerings
Table 80. Bristol-Myers Squibb Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 81. Bristol-Myers Squibb Key News & Latest Developments
Table 82. Sun Pharma Company Summary
Table 83. Sun Pharma Non-melanoma Skin Cancer Drugs Product Offerings
Table 84. Sun Pharma Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 85. Sun Pharma Key News & Latest Developments
Table 86. Qilu Pharmaceutical Company Summary
Table 87. Qilu Pharmaceutical Non-melanoma Skin Cancer Drugs Product Offerings
Table 88. Qilu Pharmaceutical Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 89. Qilu Pharmaceutical Key News & Latest Developments
Table 90. Hansoh Pharma Company Summary
Table 91. Hansoh Pharma Non-melanoma Skin Cancer Drugs Product Offerings
Table 92. Hansoh Pharma Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 93. Hansoh Pharma Key News & Latest Developments
Table 94. Celgene Corporation Company Summary
Table 95. Celgene Corporation Non-melanoma Skin Cancer Drugs Product Offerings
Table 96. Celgene Corporation Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 97. Celgene Corporation Key News & Latest Developments
Table 98. Taj Accura Company Summary
Table 99. Taj Accura Non-melanoma Skin Cancer Drugs Product Offerings
Table 100. Taj Accura Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 101. Taj Accura Key News & Latest Developments
Table 102. Khandelwal Laboratories Pvt Ltd. Company Summary
Table 103. Khandelwal Laboratories Pvt Ltd. Non-melanoma Skin Cancer Drugs Product Offerings
Table 104. Khandelwal Laboratories Pvt Ltd. Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 105. Khandelwal Laboratories Pvt Ltd. Key News & Latest Developments
Table 106. Luye Pharma Company Summary
Table 107. Luye Pharma Non-melanoma Skin Cancer Drugs Product Offerings
Table 108. Luye Pharma Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 109. Luye Pharma Key News & Latest Developments
Table 110. Beijing Youcare Company Summary
Table 111. Beijing Youcare Non-melanoma Skin Cancer Drugs Product Offerings
Table 112. Beijing Youcare Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 113. Beijing Youcare Key News & Latest Developments
Table 114. Beijing Union Pharmaceutical Factory Company Summary
Table 115. Beijing Union Pharmaceutical Factory Non-melanoma Skin Cancer Drugs Product Offerings
Table 116. Beijing Union Pharmaceutical Factory Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 117. Beijing Union Pharmaceutical Factory Key News & Latest Developments
Table 118. Hainan Haiyao Company Summary
Table 119. Hainan Haiyao Non-melanoma Skin Cancer Drugs Product Offerings
Table 120. Hainan Haiyao Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 121. Hainan Haiyao Key News & Latest Developments
Table 122. Chuntch Company Summary
Table 123. Chuntch Non-melanoma Skin Cancer Drugs Product Offerings
Table 124. Chuntch Non-melanoma Skin Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 125. Chuntch Key News & Latest Developments
List of Figures
Figure 1. Non-melanoma Skin Cancer Drugs Segment by Type in 2022
Figure 2. Non-melanoma Skin Cancer Drugs Segment by Application in 2022
Figure 3. Global Non-melanoma Skin Cancer Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-melanoma Skin Cancer Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Non-melanoma Skin Cancer Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-melanoma Skin Cancer Drugs Revenue in 2022
Figure 8. By Type - Global Non-melanoma Skin Cancer Drugs Revenue Market Share, 2018-2029
Figure 9. By Application - Global Non-melanoma Skin Cancer Drugs Revenue Market Share, 2018-2029
Figure 10. By Type - Global Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Non-melanoma Skin Cancer Drugs Revenue Market Share, 2018-2029
Figure 12. By Application - Global Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Non-melanoma Skin Cancer Drugs Revenue Market Share, 2018-2029
Figure 14. By Region - Global Non-melanoma Skin Cancer Drugs Revenue Market Share, 2018-2029
Figure 15. By Country - North America Non-melanoma Skin Cancer Drugs Revenue Market Share, 2018-2029
Figure 16. US Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Non-melanoma Skin Cancer Drugs Revenue Market Share, 2018-2029
Figure 20. Germany Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 21. France Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Non-melanoma Skin Cancer Drugs Revenue Market Share, 2018-2029
Figure 28. China Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. India Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Non-melanoma Skin Cancer Drugs Revenue Market Share, 2018-2029
Figure 34. Brazil Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Non-melanoma Skin Cancer Drugs Revenue Market Share, 2018-2029
Figure 37. Turkey Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Non-melanoma Skin Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. Pfizer Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Bausch Health Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Mayne Pharma Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Roche Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. United Laboratories Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. 3M Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Perrigo Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Biological E. Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Glenmark Pharmaceuticals Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Sichuan Med-shine Pharmaceutical Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Henan Topfond Pharmaceutical Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Regeneron (Sanofi) Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Bristol-Myers Squibb Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Sun Pharma Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Qilu Pharmaceutical Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Hansoh Pharma Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Celgene Corporation Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 58. Taj Accura Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 59. Khandelwal Laboratories Pvt Ltd. Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 60. Luye Pharma Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 61. Beijing Youcare Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 62. Beijing Union Pharmaceutical Factory Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 63. Hainan Haiyao Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 64. Chuntch Non-melanoma Skin Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)

※参考情報

非メラノーマ皮膚がん（NMSC）は、皮膚に発生するがんの一種で、特に基底細胞癌（BCC）と扁平上皮癌（SCC）が代表的なものです。これらはメラノーマとは異なり、通常は悪性度が低く、早期発見と適切な治療により高い治癒率を持っています。非メラノーマ皮膚がん治療薬は、これらのがんの治療に使用される薬剤であり、数多くの治療法とともに活用されます。

非メラノーマ皮膚がんの治療薬には、外用薬、内服薬、抗がん剤、免疫療法薬などが含まれます。これらの治療薬は、がんの種類、発生した部位、進行度、および患者の全体的な健康状態に基づいて選択されます。治療の目的は、がん細胞の増殖を抑制し、周囲の正常な組織を保護することです。

外用薬としては、5-フルオロウラシル（5-FU）やイミキモドが代表的です。5-FUは抗代謝薬で、がん細胞のDNA合成を妨げ、細胞の増殖を抑える働きがあります。イミキモドは免疫刺激剤であり、患者の免疫系を活性化することでがん細胞に対抗します。これらの薬剤は、通常、皮膚に直接塗布して使用されます。

内服薬の中には、分子標的治療薬が含まれます。これらは特定の分子や経路を標的として、がん細胞の増殖を抑える効果があります。たとえば、ソラフェニブやエルロチニブなどの薬剤は、がん細胞の成長に関与する特定の酵素を阻害します。これにより、がん細胞の生命力を低下させることが可能となります。

抗がん剤としては、一般的な化学療法薬も利用されますが、非メラノーマ皮膚がんにおいては、あまり一般的ではありません。抗がん剤は全身療法として使用されることが多く、特にHIVや腎移植後の免疫抑制状態にある患者などが対象となります。

免疫療法は、近年の皮膚がん治療において注目される分野であり、たとえばPD-1/PD-L1阻害剤が有名です。これらの治療薬は、がん細胞が免疫系の攻撃を回避するメカニズムを標的にし、免疫系ががん細胞を認識して攻撃するのを助けます。これにより、がん治療の新たな選択肢として期待されています。

治療においては、外科的切除が病変の大きさや場所に応じて優先されることが多く、手術後に外用薬や免疫療法を併用する場合もあります。また、放射線療法も一部のケースで用いられることがありますが、その適用は限定的です。

非メラノーマ皮膚がんの治療における科学技術の進展は目覚ましく、多くの臨床試験が行われています。これにより、新しい治療薬や治療法が次々と登場しており、特に個別化医療の視点から、患者一人ひとりのがんの特性に応じた治療が模索されています。

さらに、診断技術の進化も治療成績に寄与しています。デジタル技術を用いた皮膚の画像診断や、人工知能（AI）を活用した早期発見の手法が開発され、治療が必要な患者の迅速な特定が可能となっています。

患者の生活の質を向上させるための研究も進んでおり、治療による副作用を軽減するための工夫や、心理的サポートの提供も重要な課題とされています。治療法の選択肢を広げることで、患者に適したアプローチを見つけることが目指されています。

非メラノーマ皮膚がん治療薬は、今後もますます多様化していくことが予想されます。臨床データの蓄積や新しい知見の発表により、より効果的で安全な治療法が開発されることが期待されており、この分野の研究は非常に重要です。これにより、非メラノーマ皮膚がん患者が安心して治療を受けられる環境が整っていくことでしょう。

以上が、非メラノーマ皮膚がん治療薬に関する概念の概要です。これら治療薬の導入や、技術革新により、患者のリカバリーや生活の質が向上し、ひいては皮膚がんに対する理解が深まることを願っています。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 非メラノーマ皮膚がん治療薬の世界市場見通し2023年-2029年(Non-melanoma Skin Cancer Drugs Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

非メラノーマ皮膚がん治療薬の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp